3D Medicines, Inc.
HHKEX:12442.64
HKD
-0.01
(-0.38%)
ISIN
KYG8872R1011
CUSIP
G8872R101
Return %
Stock
S&P 500
1Y
-59.34
14.20
3Y
-69.32
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zhao Long Gong
- Full Time Employees
- 162
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 3 and No. 5, Laiyang Road Shandong SD China 266000
- IPO Date
- Dec 15, 2022
- Website
- 3d-medicines.com
- Similar Companies
- Business
- 3D Medicines Inc. 3D Medicines Inc. (1244.HK) is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative oncology drugs and candidates to treat various cancers, particularly aiming to manage cancer as a chronic disease. Founded in 2014 and headquartered in Qingdao, China, with additional offices in Shanghai, Beijing, Chengdu, and Xuzhou, the company operates primarily in the People's Republic of China while pursuing global development and registration. Its core products and pipeline include Envafolimab (恩维达®), the world's first subcutaneously injectable PD-L1 antibody approved for previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors, including MSI-H/dMMR advanced cancers, advanced biliary tract cancer in combination with chemotherapy, non-small cell lung cancer (NSCLC) in adjuvant/neo-adjuvant settings, advanced gastric/gastroesophageal junction cancer with chemotherapy, tumor mutation burden-high (TMB-H) advanced cancers, endometrial cancer alone or with lenvatinib, and combinations for hepatocellular carcinoma, colorectal cancer, microsatellite stable colorectal cancer with cetuximab plus or minus fruquintinib, and dMMR advanced solid tumors; 3D189, a potential WT1-targeting heteroclitic cancer vaccine in Phase I for hematological malignancies and Phase III for multi-indication tumors; 3D229 targeting GAS6/AXL in Phase III for NSCLC, ovarian, and kidney cancers; 3D1001 and 3D1002 for postoperative dental pain, tumor pain, and oncology pain in Phase II; 3D185 in Phase I for locally advanced or metastatic solid tumors; 3D197 for multi-indication tumor immunotherapy; 3D011, a multi-target kinase inhibitor, for advanced malignant solid tumors; and additional candidates leveraging mRNA technology platforms, AI-powered mRNA analysis, radioligand drug conjugates (RDCs), tumor-infiltrating lymphocytes (TIL), and chimeric antigen receptor T-cell (CAR-T) therapies. Recent developments encompass strategic collaborations, including a February 2024 partnership with Novatim (Zhejiang) Pharmaceutical Technology Co., Ltd. to explore Envafolimab combinations with KY-0118 and discuss CAR-T product rights and global trials; an August 2025 framework agreement with CATUG Biotechnology to advance mRNA-LNP technology for cancer vaccines with production support; breakthroughs in AI+mRNA-based cancer vaccines and early radiopharmaceutical signals in 2024; appointment of Gan Ding as Chief Commercial Officer in February 2025 to bolster commercialization; and recognition as a national top 500 in the 2024 "Maker China" SME innovation contest for its mRNA tumor vaccine platform.